Sept 11 (Reuters) - Zymeworks Inc ZYME.TO
* Zymeworks presents additional safety and anti-tumor activity data from the ongoing phase 1 study of zw25 at the european society for medical oncology 2017 congress ("ESMO")
* Zymeworks inc - ZW25 continues to be well-tolerated at all doses and schedules
* Zymeworks inc - dose escalation portion of phase 1 trial is complete and new expansion cohorts have begun enrolling
* Zymeworks inc - ZW25 was well-tolerated at all dose levels evaluated
* Zymeworks inc - safety and anti-tumor activity profile of ZW25 across multiple dose levels suggests potential for a wide therapeutic window